Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem

Drug Discovery Today

Volumn 17, Issue 19-20, 2012, Pages 1121-1126

  Hao, Ge Fei ^a   Yang, Guang Fu ^a   Zhan, Chang Guo ^b  

^a CENTRAL CHINA NORMAL UNIVERSITY   (China)

^b University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DARUNAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; MULTIDRUG RESISTANCE PROTEIN 1; PENICILLIN BINDING PROTEIN; ZANAMIVIR;

ACCURACY; ARTIFICIAL NEURAL NETWORK; BAYES THEOREM; BIOSYNTHESIS; CELL WALL; DRUG DESIGN; DRUG RESISTANCE; ENTHALPY; HYDROGEN BOND; MOLECULAR DYNAMICS; PROTEIN STRUCTURE; REVIEW; WILD TYPE;

COMPUTATIONAL BIOLOGY; DRUG DESIGN; DRUG RESISTANCE; HUMANS; MOLECULAR STRUCTURE; MUTATION;

EID: 84866735145     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.06.018     Document Type: Review

References (54)

1. P. Schliekelman Natural selection and resistance to HIV Nature 411 2001 545 546
2. J.M. Coffin HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy Science 267 1995 483 489
3. D.B. Longley, and P.G. Johnston Molecular mechanisms of drug resistance J. Pathol. 205 2005 275 292
4. E. Badia Tamoxifen resistance and epigenetic modifications in breast cancer cell lines Curr. Med. Chem. 14 2007 3035 3045
5. J. Qi Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors Cancer Res. 71 2011 1081 1091
6. X. Hu, and Y. Xuan Bypassing cancer drug resistance by activating multiple death pathways - a proposal from the study of circumventing cancer drug resistance by induction of necroptosis Cancer Lett. 259 2008 127 137
7. E. Jenwitheesuk, and R. Samudrala Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach Antivir. Ther. 10 2005 157 166
8. G. Pepe Prediction of HIV-1 protease inhibitor resistance by molecular modeling protocols (MMPs) using GenMol software Eur. J. Med. Chem. 43 2008 2518 2534
9. M. Layten The open structure of a multi-drug-resistant HIV-1 protease is stabilized by crystal packing contacts J. Am. Chem. Soc. 128 2006 13360 13361
10. T. Hou, and R. Yu Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance J. Med. Chem. 50 2007 1177 1188
11. H. Ode Mechanism of drug resistance due to N88S in CRF01-AE HIV-1 protease, analysed by molecular dynamics simulations J. Med. Chem. 50 2007 1768 1777
12. I. Stoica Rapid and accurate prediction of binding free energies for saquinavir-bound HIV-1 proteases J. Am. Chem. Soc. 130 2008 2639 2648
13. G.F. Hao Understanding the mechanism of drug resistance due to a codon deletion in protoporphyrinogen oxidase through computational modeling J. Phys. Chem. B 113 2009 4865 4875
14. I.S. Moreira Computational alanine scanning mutagenesis - an improved methodological approach J. Comput. Chem. 28 2007 644 654
15. G.F. Hao Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors J. Phys. Chem. B 114 2010 9663 9676
16. Z.W. Cao Computer prediction of drug resistance mutations in proteins Drug Discov. Today 10 2005 521 529
17. T. Hou Predicting drug resistance of the HIV-1 protease using molecular interaction energy components Proteins 74 2009 837 846
18. J. Zhang Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance Proc. Natl. Acad. Sci. U.S.A. 107 2010 1321 1326
19. Y. Tie High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains J. Mol. Biol. 338 2004 341 352
20. A.K. Ghosh Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance J. Med. Chem. 49 2006 5252 5261
21. A. Michalczyk Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR Bioorg. Med. Chem. 16 2008 3482 3488
22. A.K. Ghosh Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance J. Med. Chem. 52 2009 7689 7705
23. X. Wang Design, synthesis, and biological evaluation of 1-[(2-Benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile J. Med. Chem. 55 2012 2242 2250
24. E. Lefebvre, and C.A. Schiffer Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir AIDS Rev. 10 2008 131 142
25. A.K. Ghosh Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors ChemMedChem 5 2010 1850 1854
26. W. Wang, and P.A. Kollman Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance Proc. Natl. Acad. Sci. U.S.A. 98 2001 14937 14942
27. C. Fattorusso Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity J. Med. Chem. 48 2005 7153 7165
28. S.Q. Wang Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases Biochem. Biophys. Res. Commun. 354 2007 634 640
29. S. Butini Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations J. Med. Chem. 52 2009 1224 1228
30. R. Ishima Highly conserved glycine 86 and arginine 87 residues contribute differently to the structure and activity of the mature HIV-1 protease Proteins 78 2010 1015 1025
31. C. Contreras-Martel Structure-guided design of cell wall biosynthesis inhibitors that overcome beta-lactam resistance in Staphylococcus aureus (MRSA) ACS Chem. Biol. 6 2011 943 951
32. N.M. King Combating susceptibility to drug resistance: lessons from HIV-1 protease Chem. Biol. 11 2004 1333 1338
33. M. Nijhuis A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism PLoS Med. 4 2007 E36
34. M.D. Altman Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease Proteins 70 2008 678 694
35. R.N. Jorissen Additivity in the analysis and design of HIV protease inhibitors J. Med. Chem. 52 2009 737 754
36. V. Kairys Toward the design of mutation-resistant enzyme inhibitors: further evaluation of the substrate envelope hypothesis Chem. Biol. Drug Des. 74 2009 234 245
37. M.N. Nalam Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance J. Virol. 84 2010 5368 5378
38. M. Kolli Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate Virology 347 2006 405 409
39. R. Morphy, and Z. Rankovic Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 48 2005 6523 6543
40. M. Ji Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia Br. J. Haematol. 145 2009 648 656
41. S. de Jong Death receptor ligands, in particular TRAIL, to overcome drug resistance Cancer Metastasis Rev. 20 2001 51 56
42. C. Avendano, and J.C. Menendez Inhibitors of multidrug resistance to antitumor agents (MDR) Curr. Med. Chem. 9 2002 159 193
43. H. Ishikita, and A. Warshel Predicting drug-resistant mutations of HIV protease Angew. Chem. Int. Ed. 47 2008 697 700
44. T. Hou Evaluating the potency of HIV-1 protease drugs to combat resistance Proteins 71 2008 1163 1174
45. T.E. Balius, and R.C. Rizzo Quantitative prediction of fold resistance for inhibitors of EGFR Biochemistry 48 2009 8435 8448
46. X.L. Zhu Computational simulations of the interactions between acetyl-coenzyme-A carboxylase and clodinafop: resistance mechanism due to active and nonactive site mutations J. Chem. Inf. Model. 49 2009 1936 1943
47. M. Lapins, and J.E. Wikberg Proteochemometric modeling of drug resistance over the mutational space for multiple HIV protease variants and multiple protease inhibitors J. Chem. Inf. Model. 49 2009 1202 1210
48. S.Y. Rhee Genotypic predictors of human immunodeficiency virus type 1 drug resistance Proc. Natl. Acad. Sci. U.S.A. 103 2006 17355 17360
49. I. Bonet Predicting Human Immunodeficiency Virus (HIV) drug resistance using recurrent neural networks International Work-Conference on the Interplay Between Natural and Artificial Computation 2007 234 243
50. H. Saigo Mining complex genotypic features for predicting HIV-1 drug resistance Bioinformatics 23 2007 2455 2462
51. A. Srisawat, and B. Kijsirikul Combining classifiers for HIV-1 drug resistance prediction Protein Pept. Lett. 15 2008 435 442
52. D. Wang A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy Artif. Intell. Med. 47 2009 63 74
53. A.M. Almerico Docking and multivariate methods to explore HIV-1 drug-resistance: a comparative analysis J. Comput. Aided Mol. Des. 22 2008 287 297
54. K. Deforche Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment Bioinformatics 24 2008 34 41